scholarly journals Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis

2022 ◽  
Vol 25 (1) ◽  
pp. 1
Author(s):  
Saeedeh Talebi ◽  
Andrew S. Day ◽  
Majid Khadem Rezaiyan ◽  
Golnaz Ranjbar ◽  
Mitra Zarei ◽  
...  
2021 ◽  
Vol 71 (9) ◽  
Author(s):  
Danish Abdul Aziz ◽  
Syeda Khadija Fatima ◽  
Hasan Nawaz Tahir

Objective: To ascertain major risk factors associated with pulmonary exacerbation and pulmonary function decline in cystic fibrosis. Method: The systematic review was conducted at Aga Khan University, Karachi, in September 2018, and comprised electronic search of PubMed, Ovid, Science Direct and Cumulative Index of Nursing and Allied Health Literature databases of studies conducted from January 1990 to September 2018 which were categorised into 3 sets; 1990-98, 1999-2007 and 2008-18. Studies included for review focussed on articles with pulmonary exacerbation as the health outcome indicator, and had diagnosis of cystic fibrosis as the inclusion criteria, while risk factors were the exposure terms used in the search process. References in bibliographies of the included studies were also systematically searched for relevant documents. Results: Of the 60 studies obtained, 31(51.7%) were selected; 2(6.45%) from 1990-98, 7(22.58%) from 1999-2007 and 22(70.96%) from 2008-18. Overall, 17(54.83%) were cohort studies, 7(22.5%) were cross-sectional studies, 3(9.6%) were case-control studies, 3(9.6%) were randomised controlled trials and 1(3.2%) was systematic review and meta-analysis. In terms of major risk factors, genetic mutations were cited by 4(12.9%) studies, infections and inflammatory biomarkers by 15(48.4%), nutritional deficiencies by 9(29%) and geographical and socioeconomic status by 3(9.6%) studies. Conclusion: Early identification and recognition of risk factors associated with pulmonary exacerbation can have an explicit impact on its management, leading to decreased morbidity and mortality burden in cystic fibrosis cases. Key Words: Pulmonary exacerbation, Cystic fibrosis, Risk factors, Systematic review. Continuous...


2020 ◽  
Vol 51 ◽  
pp. 101279 ◽  
Author(s):  
Joel Reiter ◽  
Alex Gileles-Hillel ◽  
Malena Cohen-Cymberknoh ◽  
Dennis Rosen ◽  
Eitan Kerem ◽  
...  

Pancreatology ◽  
2020 ◽  
Vol 20 ◽  
pp. S121
Author(s):  
M. Juhász ◽  
O. Varannai ◽  
D. Németh ◽  
K. Ocskay ◽  
Z. Szakács ◽  
...  

2021 ◽  
Vol 3 (2) ◽  
Author(s):  
Zhongsheng Cao ◽  
Chenglong Ye ◽  
Lunan Li ◽  
Xiaoge Geng ◽  
Wensheng Pan ◽  
...  

2012 ◽  
Vol 50 (4) ◽  
pp. 360-369
Author(s):  
K.I. Macdonald ◽  
A. Gipsman ◽  
A. Magit ◽  
M. Fandino ◽  
E. Massoud ◽  
...  

Introduction: The role of endoscopic sinus surgery (ESS) in patients with cystic fibrosis (CF) is not clearly defined. Objective: TO perform a systematic review of subjective and objective outcomes of ESS in CF. Methods: A systematic review was performed using the keywords 'sinusitis,' 'sinus surgery,' 'nasal polyps' and 'cystic fibrosis.' The quality of papers was assessed using the NICE scoring scale. Outcomes included safety, subjective symptoms, objective endoscopy scores, days spent in hospital, courses of antibiotics, and pulmonary function tests (PFTs). Results: Nineteen studies involving 586 patients were included in the review. There were four prospective cohort trials, and three were rated as good quality. There were no major complications attributable to ESS. There was consistent evidence in four cohort studies of improved sinonasal symptoms, including nasal obstruction, facial pain, headaches, rhinorrhea and olfaction. Three studies reported conflicting results in post-operative endoscopy scores. Three studies showed a decrease in days spent in hospital, and two showed a significant decrease in courses of intravenous antibiotics. A recent study, however, did not show a difference in either days spent in hospital or courses of antibiotics. Pulmonary function tests were not improved by ESS in six cohort trials, and one small study found significant improvement. A meta-analysis of FEV1 scores confirmed no significant difference. Conclusion: THE most consistent findings of this review were that ESS in patients with CF is safe, produces symptomatic benefit, and does not consistently improve PFTs. There were more conflicting results with regards to endoscopy scores, days spent in hospital, and courses of intravenous antibiotics. Future prospective studies, utilizing validated quality of life, symptom and endoscopy scales, are needed to further elucidate the role of ESS in the management of chronic rhinosinusitis in CF patients.


2019 ◽  
Vol 18 (3) ◽  
pp. 407-415 ◽  
Author(s):  
Angela Koutsokera ◽  
Rhea A. Varughese ◽  
Jenna Sykes ◽  
Ani Orchanian-Cheff ◽  
Prakesh S. Shah ◽  
...  

Respirology ◽  
2014 ◽  
Vol 19 (3) ◽  
pp. 321-329 ◽  
Author(s):  
Qibiao Wu ◽  
Weixing Shen ◽  
Haibo Cheng ◽  
Xiqiao Zhou

Sign in / Sign up

Export Citation Format

Share Document